GLP-1
GLP
Metabolic
CAS
107444-51-9
Molecular Weight
4113
Da
Human RCT
GLP-1 (Glucagon-Like Peptide-1) is a naturally occurring hormone whose synthetic analogs — including semaglutide (Ozempic, Wegovy) and liraglutide — have become among the most prescribed medications in the world for type 2 diabetes and obesity. FDA approved with an extensive clinical evidence base. Works by stimulating insulin release, suppressing appetite, and slowing gastric emptying. Requires a prescription through a licensed provider.
Injectable · Oral
Intranasal Suitable
No
Prescription
Community Signal
Community signal is vast and one of the most documented in the biohacking and weight loss space. r/Semaglutide, r/WeightLossAdvice, and r/GLP1Sourcing have accumulated years of patient reports spanning appetite suppression, weight trajectory, and side effect profiles. Appetite reduction is described as qualitatively different from willpower-based restriction, many users describe "food noise" going quiet for the first time. Side effects are frequently discussed: nausea during dose escalation, constipation, and muscle mass loss concerns are common threads. Compounded semaglutide sourcing discussions are a major community topic given pricing dynamics. The community is generally sophisticated about the need for sustained lifestyle change alongside GLP-1 use.
We break down one compound like this every week
The Honest Dose — free, no sponsorships, no agenda. Just the evidence.
What It Is
GLP-1 (Glucagon-Like Peptide-1) is a naturally occurring incretin hormone produced primarily by L-cells in the small intestine and colon in response to food intake. It plays a central role in regulating blood sugar, appetite, and digestion. The GLP-1 peptides covered on PeptideClear refer specifically to synthetic GLP-1 receptor agonists, pharmaceutical compounds that mimic and extend the action of natural GLP-1. The most well known include semaglutide (Ozempic, Wegovy) and liraglutide (Victoza, Saxenda). GLP-1 receptor agonists represent one of the most significant pharmaceutical developments of the past decade, transforming treatment of type 2 diabetes and obesity.
Mechanism of Action
GLP-1 receptor agonists bind to GLP-1 receptors throughout the body, primarily in the pancreas, brain, stomach, and heart. In the pancreas they stimulate glucose-dependent insulin secretion and suppress glucagon release, lowering blood sugar without causing hypoglycemia when glucose levels are normal. In the brain they act on hypothalamic appetite centers to reduce hunger and increase satiety. In the stomach they slow gastric emptying, prolonging the feeling of fullness after meals. Cardiovascular benefits observed in clinical trials are thought to result from direct GLP-1 receptor activity in cardiac and vascular tissue.
Use Cases
GLP-1 receptor agonists are FDA approved for type 2 diabetes management and chronic weight management. In clinical practice they are used for significant and sustained weight loss, blood sugar regulation, cardiovascular risk reduction in diabetic patients, and increasingly for non-alcoholic fatty liver disease. Emerging research is investigating their potential in neurodegenerative conditions including Alzheimer's and Parkinson's disease, addiction, and polycystic ovary syndrome (PCOS).
Known Risks
GLP-1 receptor agonists are among the most studied compounds in this catalog given their FDA approval status. Known side effects include nausea, vomiting, diarrhea, and constipation — particularly during dose escalation — which are the most common reasons for discontinuation. More serious considerations include: risk of pancreatitis, gallbladder disease, increased heart rate, and a boxed warning for thyroid C-cell tumors observed in rodent studies (clinical significance in humans remains unclear). Contraindicated in individuals with personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2. Not recommended during pregnancy. Muscle mass loss alongside fat loss is an increasingly recognized concern with long-term use.
Available Forms
Injectable (subcutaneous, weekly or daily depending on formulation) and oral tablet (semaglutide oral — Rybelsus). Injectable remains the most bioavailable and widely prescribed form. Compounded semaglutide and tirzepatide have been widely available through telehealth platforms but face increasing FDA scrutiny as brand name shortages resolve.
Regulatory Status
GLP-1 receptor agonists are FDA approved prescription medications. Branded versions (Ozempic, Wegovy, Victoza, Saxenda, Mounjaro, Zepbound) require a prescription. Compounded versions have been available through 503A and 503B compounding pharmacies during periods of FDA-declared shortage but this pathway is narrowing as of 2025. Access requires a licensed prescriber.
Sources
https://pubmed.ncbi.nlm.nih.gov/29617641/
https://pubmed.ncbi.nlm.nih.gov/33567185/
https://pubmed.ncbi.nlm.nih.gov/27633186/
Similar Compounds
Retatrutide, Semaglutide, Tirzepatide, MK-677
Enjoyed this profile? Get one compound broken down in depth every week in The Honest Dose.
Join The Honest Dose →Last Reviewed